Cleared Traditional

REFLOTRON CREATINE KINASE TEST TABS (K904102) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K904102 · Boehringer Mannheim Corp. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1990
Decision
21d
Days
Class 2
Risk

K904102 is an FDA 510(k) clearance for the REFLOTRON CREATINE KINASE TEST TABS. Classified as Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes (product code CGS), Class II - Special Controls.

Submitted by Boehringer Mannheim Corp. (Indianapolis, US). The FDA issued a Cleared decision on September 27, 1990 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1215 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Boehringer Mannheim Corp. devices

Submission Details

510(k) Number K904102 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 06, 1990
Decision Date September 27, 1990
Days to Decision 21 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 88d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1215
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes

All 45
Devices cleared under the same product code (CGS) and FDA review panel - the closest regulatory comparables to K904102.
CREATINE KINASE (CK) TEST ITEM #65411
K924704 · Em Diagnostic Systems, Inc. · Oct 1992
OLYMPUS CREATINE KINASE REAGENT
K922459 · Olympus Corp. · Jul 1992
CREATINE KINASE MB TEST ITEM NUMBER 5A46
K914361 · Em Diagnostic Systems, Inc. · Dec 1991
CREATINE KINASE TEST (CK) ITEM NUMBER 65411
K903333 · Em Diagnostic Systems, Inc. · Aug 1990
CREATINE KINASE-MB TEST (MB-DS) ITEM #67655
K902483 · Em Diagnostic Systems, Inc. · Jul 1990
REP(TM) CK-2 STAT KIT, CAT. NO. 3074
K893007 · Helena Laboratories · Jul 1989